IDELVION USES TRUSTED ALBUMIN FUSION TECHNOLOGY TO EXTEND FACTOR IX TIME IN CIRCULATION
Albumin is a naturally occurring protein that was specifically selected for its prolonged half‑life
Recombinant albumin IDELVION is formed by fusing recombinant albumin, known for its long half-life and low risk for immunogenic reaction, with recombinant Factor IX (rFIX).
Cleavable peptide linker Upon initiation of the coagulation cascade, recombinant albumin is cleaved, only releasing activated Factor IX when needed for coagulation.
Recombinant Factor IX (rFIX) The rFIX remains linked to the recombinant albumin via a cleavable peptide linker so it remains inactive until it’s needed to control a bleed.
-
1
Recombinant albumin IDELVION is formed by fusing recombinant albumin, known for its long half-life and low risk for immunogenic reaction, with recombinant Factor IX (rFIX).
-
2
Cleavable peptide linker Upon initiation of the coagulation cascade, recombinant albumin is cleaved, only releasing activated Factor IX (FIX) when needed for coagulation.
-
3
Recombinant Factor IX (rFIX) The rFIX remains linked to the recombinant albumin via a cleavable peptide linker so it remains inactive until it’s needed to control a bleed.
Patients who started and stayed on prophylaxis prove IDELVION has powerful efficacy with both 7- and 14-day dosing†
VIEW EFFICACY DATA*Once well-controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
†Of the 23 subjects in Arm 2, 19 were transitioned from on-demand to 7-day prophylaxis. The median AsBR during prophylaxis treatment was 0.7 (range: 0 to 4.2). Data for Arms 1 and 2 based on matched-pairs design.